<DOC>
	<DOC>NCT00349193</DOC>
	<brief_summary>Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has immunomodulating properties. In a previous clinical study laquinimod showed evidence of biological activity by reducing the number of acute brain lesions. The duration of the current study is 36 weeks.</brief_summary>
	<brief_title>A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<criteria>1. Willing and able to give written informed consent 2. Confirmed MS diagnosis as defined by the McDonald criteria 3. RR MS disease course. 4. At least one gadoliniumenhanced lesion on screening MRI 5. Women of childbearing potential must practice a reliable method of birth control. 6. Must understand the requirements of the study and agree to comply with the study protocol. 1. Subjects who suffer from any form of progressive MS. 2. Any condition which the investigator feels may interfere with participation in the study. 3. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, 4. Subjects who received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening 5. Previous treatment with immunomodulators within two months prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
</DOC>